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Objective: Available treatment for obesity and type 2 diabetes mellitus (T2DM) is suboptimal. Thus, identifying novel molecular target(s) exerting
protective effects against these metabolic imbalances is of enormous medical signiﬁcance. Sirt6 loss- and gain-of-function studies have
generated confounding data regarding the role of this sirtuin on energy and glucose homeostasis, leaving unclear whether activation or inhibition
of SIRT6 may be beneﬁcial for the treatment of obesity and/or T2DM.
Methods: To address these issues, we developed and studied a novel mouse model designed to produce eutopic and physiological over-
expression of SIRT6 (Sirt6BAC mice). These mutants and their controls underwent several metabolic analyses. These include whole-blood reverse
phase high-performance liquid chromatography assay, glucose and pyruvate tolerance tests, hyperinsulinemic-euglycemic clamp assays, and
assessment of basal and insulin-induced level of phosphorylated AKT (p-AKT)/AKT in gastrocnemius muscle.
Results: Sirt6BAC mice physiologically overexpress functionally competent SIRT6 protein. While Sirt6BAC mice have normal body weight and
adiposity, they are protected from developing high-caloric-diet (HCD)-induced hyperglycemia and glucose intolerance. Also, Sirt6BAC mice
display increased circulating level of the polyamine spermidine. The ability of insulin to suppress endogenous glucose production was signiﬁcantly
enhanced in Sirt6BAC mice compared to wild-type controls. Insulin-stimulated glucose uptake was increased in Sirt6BAC mice in both
gastrocnemius and soleus muscle, but not in brain, interscapular brown adipose, or epididymal adipose tissue. Insulin-induced p-AKT/AKT ratio
was increased in gastrocnemius muscle of Sirt6BAC mice compared to wild-type controls.
Conclusions: Our data indicate that moderate, physiological overexpression of SIRT6 enhances insulin sensitivity in skeletal muscle and liver,
engendering protective actions against diet-induced T2DM. Hence, the present study provides support for the anti-T2DM effect of SIRT6 and
suggests SIRT6 as a putative molecular target for anti-T2DM treatment.
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1. INTRODUCTION
The prevalence of obesity and T2DM has risen signiﬁcantly in the last
decades. According to the World Health Organization T2DM and/or
obesity are estimated to affect hundreds of millions worldwide (http://
www.who.int/mediacentre/factsheets/fs311/en/ and http://www.who.
int/mediacentre/factsheets/fs312/en/). Signiﬁcant contributors to the
rapid increase in the incidence of obesity and T2DM include recent
lifestyle changes such as chronic consumption of hyper-caloric diets
[1]. Unfortunately, current anti-obesity and -T2DM treatments are still
suboptimal due to their side effects and the fact that long-lasting and
debilitating morbidities (e.g.: heart disease, neuropathy, and hyper-
tension) are still too often associated with these maladies [1e5]. Thus,
development of more effective anti-obesity and -T2DM treatments is
urgently needed. To these ends, the identiﬁcation of novel molecular
target(s) exerting protective effects against dietary obesity and/or
T2DM is of paramount medical signiﬁcance.
Recent genetic and pharmacological studies have identiﬁed sirtuins,
which are nicotinamide adenine dinucleotide-dependent enzymes
exerting post-translational modiﬁcations of their target proteins, as
potential therapeutic targets for improving HCD-induced metabolic
imbalances [6e15]. SIRT6, one of the seven mammalian sirtuins, is a
lysine-deacetylase and mono-ADP-ribosyl-transferase with pleiotropic
effects [16]. However, the role of SIRT6 in metabolism is controversial.
For example, Sirt6 knockout mice exhibit reduced adipose tissue mass
and hypoglycemia [17]. SIRT6 deﬁciency also leads to attenuation of
SIRT6-dependent transcriptional silencing resulting in increased
expression of genes involved in glycolysis and glucose transport
[18,19]. Of note, secretion of tumor necrosis factor-alpha (TNF-a),
which is known to exert detrimental actions on energy homeostasis
and insulin sensitivity [20], is diminished following knock-down of
SIRT6 [21]. Therefore, according to these observations, systemic de-
livery of SIRT6 inhibitors should diminish adiposity, increase insulin
sensitivity, glucose uptake and utilization, and consequently improve
obesity and T2DM. However, in contrast to this notion, ubiquitous and
supra-physiological overexpression of SIRT6 also leads to reduced
adiposity and improved glucose metabolism in mice fed on a HCD [22].
Furthermore, adenoviral-mediated overexpression of SIRT6 in liver of
diabetic mice suppresses hepatic glucose production and improves
hyperglycemia [23]. Hence, these latter results suggest that systemic
delivery of SIRT6 activators should bring about beneﬁcial effects in the
context of obesity and T2DM.
Based on the aforementioned data, it is unclear whether means to
inhibit or enhance SIRT6 protein activity should be sought in order to
treat obesity and/or T2DM. Also, the tissues underlying the effect of
SIRT6 on whole-body glucose homeostasis are unknown. In order to
address these issues, we developed and studied a novel mouse model
designed to produce eutopic and physiological overexpression of SIRT6
(Sirt6BAC mice).
2. MATERIAL AND METHODS
2.1. Animals
Mice were housed with chow diet and water available ad libitum in
light (12-hour light/12-hour dark cycles) and temperature (20e
22 C) controlled environments. Male mice were used for all ex-
periments. Mice in HCD cohorts were fed a 58 kcal% fat w/sucrose
diet (Open Source Diet Product #D12331 Research Diets Inc.)
beginning at 8 weeks of age. Care of mice was within the Institutional
Animal Care and Use Committee (IACUC) guidelines, and procedures
were approved by the University of Texas Southwestern MedicalMOLECULAR METABOLISM 4 (2015) 846e856  2015The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comCenter IACUC and the ethical commission of the Canton of Geneva,
Switzerland.
2.2. Generation of Sirt6BAC mice
A bacterial artiﬁcial chromosome (BAC) possessing 185.7 kb (70.7 kb
upstream and 109.3 kb downstream) of unmodiﬁed mouse genomic
DNA sequences ﬂanking the Sirt6 gene (BAC clone RP23-352G18,
BACPAC RESOURCES, CHILDREN’S HOSPITAL Oakland, CA, USA)
was puriﬁed as previously described [18] and used as template
sequence for PCR reactions with the primer sets:
50GACTGGGACCACACCAGAGT and 50GTGAGAGCGGGAAGAGTACG;
50AGGTGCCTGTGGACACTACC and 50CAGGGGACACACTGGTTTCT;
50CTGTCCACCTGTTGGAAGGT and 50CTTCTGGGTCACCACAAGGT;
50CATGAATGCTGTTTGGTTGG and 50ATGCTGTAGGGTGGGAAGTG;
50CCTTTGGAAAAGCAGTCAGC and 50GAACTCCTGGCAAGTCGAAG;
50CCACTGGGTCAGTCACACAC and 50AGGACTCCACCTGGATTGTG. Upon
observing the expected size of each amplicons, the puriﬁed BAC DNA
was then electroporated into EL250 bacteria rendered electro-
competent as previously described [24]. loxP sequences contained in
the pBACe3.6 backbone of RP23-352G18 BAC DNA were replaced via
homologous recombination [25] by an ampicillin resistance gene
cassette generated via PCR ampliﬁcation of a PGEM-T-Easy vector
template with the primer sets:
50GATAAACTACCGCATTAAAGCTTATCGATGATAAGCTGTCAAACATGAG-
AATTGATCCGGATATATGAGTAAACTTGGTCTGAC and
50GTTAACCGGGCTGCATCCGATGCAAGTGTGTCGCTGTCGACGGTGACC-
CTATAGTCGAGGCGGTATTTTCTCCTTACGCATC. The modiﬁed RP23-
352G18 BAC DNA was then puriﬁed and microinjected in its circular
state into pronuclei of fertilized embryos of C57Bl/6J mice using
standard methods [24]. By genotyping of tail biopsies using the
following primer sets
50TTGCTCTTGCGGGAAGCCCG and 50GATACCGAGGGCGCCGTTCG
(speciﬁc to the pBACe3.6 backbone sequence of RP23-352G18);
50TTGCTGCATCAGGAGGGCGC and 50TCCCACAATGCCCCGCTTCG
(speciﬁc to the wild-type Sirt6 allele) three mice were identiﬁed having
germ-line incorporation of RP23-352G18 BAC DNA. These three
Sirt6BAC mice were bred to wild-type C57Bl/6J mice establishing
three distinct Sirt6BAC lines. Data shown here were obtained from the
study of the line displaying two to four fold expression of SIRT6
compared to wild-type littermates.
2.3. Generation of Sirt6BAC; Sirt6/mice
Sirt6BAC mice were bred to mice heterozygous for the Sirt6 null allele
(Sirt6þ/) [17]. F1 offspring were mated (Sirt6þ/  Sirt6þ/;
Sirt6BAC) to generate F2 breeder mice. From these F2 breeding pairs
(Sirt6þ/  Sirt6þ/; Sirt6BAC), F3 cohorts were obtained for
experimental study including wild-types, mice harboring the Sirt6BAC
(Sirt6BAC), or Sirt6 knockout mice harboring Sirt6BAC (Sirt6BAC;
Sirt6/). To determine whether a mouse contained none, one, or two
endogenous wild-type Sirt6 sequences, we utilized a multiplex Taq-
Man qPCR Copy Number genotyping analysis in which the commer-
cially available Transferrin Receptor (Tfrc) (VIC dye-labeled probe) from
Applied Biosystems (Foster City, CA, USA) was used as endogenous
reference copy-number and the commercially available Escherichia
coli b-galactosidase Mr00529369_cn (FAM dye-labeled probe) from
Applied Biosystems (Foster City, CA, USA) was used to quantify the
endogenous wild-type Sirt6 allele copy number. Of note, the endog-
enous wild-type Sirt6 sequences were swapped with the b-galacto-
sidase sequences in Sirt6þ/ mice [17]. Thus, mice bearing two of the
endogenous wild-type Sirt6 alleles were found to have zero copies of
the b-galactosidase allele, whereas mice bearing one of theaccessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 847
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b-galactosidase allele, and mice lacking both of the endogenous wild-
type Sirt6 alleles were found to have two copies of the b-galactosidase
allele.
2.4. Western blot
Tissues were lysed with RIPA buffer (R0278 Sigma Aldrich) with
1:100 dilution of protease inhibitor cocktail (P8340 Sigma Aldrich).
Equal amounts of protein lysates (20 mg) were separated via SDS-
PAGE and transferred to nitrocellulose membranes by electroblotting.
Subsequently, the membranes were blocked using LI-COR Odyssey
blocking buffer (927e40000) for 2 h at room temperature, then placed
in primary antibody incubation (rabbit polyclonal anti-SIRT6 [Abcam
ab62739] 1:3000 dilution and mouse monoclonal anti-bActin [Sigma
Aldrich A5316] in LI-COR Odyssey blocking buffer w/0.1%
Tween-20, overnight at 4 C. After washing the membranes
3  10 min in PBS w/0.1% Tween-20, they were incubated at room
temperature in darkness for 2 h with ﬂuorescently conjugated sec-
ondary antibodies (goat anti-rabbit LI-COR IRDye 800CW [926e
32211] 1:5,000 and goat anti-mouse LI-COR IRDye 680 [926e
32220] 1:10,000) in Odyssey blocking buffer w/0.1% Tween-20,
0.01%SDS. The membranes were imaged with a LI-COR Odyssey
infrared imager. SIRT6 speciﬁc bands (w37kD) were quantiﬁed
relative to housekeeping protein level using LI-COR Odyssey Image
Studio software. p-AKT/AKT ratio was assessed as previously
described [10].
2.5. Quantitative real-time PCR (qPCR)
Tissues were lysed in TRIzol reagent in order to extract total RNA.
cDNA was reverse transcribed from these puriﬁed RNA samples with
Invitrogen SuperScript III reverse transcriptase. Genes present on
RP23-352G18 BAC were assayed via qPCR gene expression analysis
to determine the levels of mRNA transcript expression. qPCR gene
expression analysis was performed using inventoried TaqMan gene
expression assays (Applied Biosystems). These genes included: AES
(Mm01148854_g1), Ankrd24 (Mm01147213_m1), BC025920
(Mm02763635_s1), Gna11 (Mm01172792_m1), Gna15
(Mm00494669_m1), Tle2 (Mm00498094_m1), Tle6
(Mm00475103_m1), and Sirt6 (Mm01149042_m1). Expression levels
were measured with an Applied Biosystems 7900HT Sequence
Detection System with SDS2.1 software. Baseline values of ampliﬁ-
cation plots were set automatically and threshold values were kept
constant. The mRNA levels were expressed as arbitrary units and were
obtained by dividing the averaged sample values (in triplicate) for each
gene by that of the control housekeeper 18S rRNA (Mm03928990_g1).
2.6. Body weight and body composition
Mice were weighed every other week beginning at 8 weeks of age.
Body composition was determined monthly beginning at 8 weeks of
age using the EchoMRI-100 quantitative nuclear magnetic reso-
nance system providing precise measurements of whole body fat and
lean mass.
2.7. Blood chemistry
Mice were singly housed in the morning (9ame12 pm) in cages with
fresh bedding and access to water, but without food during this time
period to ensure that the experimental measurements were not
affected by postprandial effects. Fasting levels were gathered from
blood samples obtained from mice fasted over-night. Glycemia
measurements were taken from tail blood samples with OneTouch
Ultra 2 glucometer with OneTouch Ultra Blue Test Strips.848 MOLECULAR METABOLISM 4 (2015) 846e856  2015 The Authors. Published by Elsevier GmbImmediately following, 50 mL of blood was collected in tubes at
room temperature for ﬁve minutes before placing into ice. The blood
samples were then centrifuged at 2,000  g for 10 min at 4 C. The
blood serum supernatant was then pipetted into a new tube for
storage at 80 C. Blood chemistry was assessed as previously
described [9,10,26].
2.8. Intraperitoneal glucose and pyruvate tolerance tests
Intraperitoneal glucose tolerance tests (IPGTT) and intraperitoneal
pyruvate tolerance tests (IPPTT) were performed in male, age-matched
mouse cohorts with similar body weights. Mice were singly housed
and fasted overnight (6pme10 am) in cages with fresh bedding and
access to water, but without food during this time period to ensure that
the experimental measurements were under fasting conditions. An
hour before the in vivo experiment, mice were weighed to determine
the dosage of glucose (1.5 g glucose per kg bodyweight) or pyruvate
(2 g pyruvate per kg bodyweight) to be administered. Just prior to
injecting the glucose (or pyruvate) bolus, fasting glycemia was
measured from tail blood samples with an AlphaTRAK blood gluc-
ometer. The glucose (0.15 g glucose/mL 0.9% saline) or pyruvate
(0.2 g sodium pyruvate/mL 0.9% saline) solution was then injected into
the intraperitoneal cavity of each mouse. Blood glucose measurements
were taken from tail blood samples at times indicated in the ﬁgures.
2.9. Hyperinsulinemic-euglycemic clamp
Clamp was performed in male, standard chow-fed, age-matched mice
with similar body weights. 5 days prior to the experiment, mice were
anesthetized using isoﬂurane and a catheter was surgically implanted
in the right jugular vein and exteriorized above the neck as previously
described [27]. Hyperinsulinemic-euglycemic clamps were then per-
formed in these 14e16 week old, conscious, unrestrained cathe-
terized mice. Mice were fasted 5 h prior to the start of the experiment
(t ¼ 0 min). At t ¼ 120 min, an infusion of [3-3H]glucose (0.05 mCi/
min) was initiated. At t ¼ 15 and 5 min, blood samples were
collected from the tail vein to measure basal blood glucose and plasma
insulin as well as to calculate the rate of endogenous glucose
appearance (EndoRa) and glucose disposal (Rd). At t ¼ 0 min, a
continuous insulin infusion (4 mU/kg bodyweight/min.) was used to
induce hyperinsulinemia and the infusion of [3-3H]glucose was
increased to 0.1 mCi/min. Blood samples were then taken every 10 min
to measure blood glucose, and 50% dextrose was infused as needed
to maintain target euglycemia (120 mg/dL). This target was chosen
because it was the average basal glycemia of the two groups. Addi-
tional blood samples were taken every 10 min from t¼ 100e120 min
(steady state clamp) to determine plasma insulin and calculate glucose
turnover. After the blood sample was taken at t ¼ 120 min, a 13 mCi
bolus of 2[14C]deoxyglucose tracer was administered for the mea-
surement of tissue-speciﬁc glucose uptake (Rg). Blood samples were
obtained at t¼ 122, 130, 137, 145 min to assess blood glucose and 2
[14C]deoxyglucose speciﬁc activity. Mice were then anesthetized using
chloral hydrate. Brain, interscapular brown adipose tissue, liver,
epididymal white adipose tissue, gastrocnemius, and soleus muscle
were ﬂash-frozen in liquid nitrogen for storage at 80 C for further
analysis. Plasma concentrations of [3-3H]glucose were determined
following deproteinization of plasma samples with zinc sulfate and
barium hydroxide. Basal glucose turnover and insulin-stimulated Rd
was determined as the ratio of the [3-3H]glucose infusion rate to the
speciﬁc activity of plasma [3-3H]glucose at the end of basal period and
during clamp steady state, respectively. EndoRa during the clamp was
determined by subtracting steady state GIR from Rd. Rg was deter-
mined by measuring the accumulation of phosphorylated 2[14C]H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Sirt6BAC mice eutopically overexpress mouse SIRT6. (A) Schematic representation of the RP23-352G18 (BACPAC Resources, Children’s Hospital Oakland Research
Institute) BAC DNA construct containing the mouse Sirt6 gene used to generate Sirt6BAC mice. (B) Anti-SIRT6 Western blots of tissues from Sirt6BAC and wild-type standard-diet-
fed mice on a pure C57Bl/6 genetic background. (Each lane represents tissue from a single mouse). For each tissue, data were gathered from the same membrane. The same
membrane was digitally separated to improve clarity. (C) Quantiﬁcation of the relative SIRT6/bACTIN expression shown in panel B (n ¼ 4 per group). (D) qPCR measurements of
brain, gastrocnemius and liver gene transcripts present in wild-type, Sirt6BAC, and Sirt6BAC; Sirt6/ standard-diet-fed mice on a C57Bl/6; 129SvJ mixed genetic background
(n ¼ 6e8 per group). Values are mean  S.E.M. Statistics were analyzed using unpaired two-tailed t-test when 2 groups were compared and one-way ANOVA with Tukey
correction for multiple comparisons when 3 or more groups were compared (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).deoxyglucose in dissected tissues and the disappearance of 2[14C]
deoxyglucose from blood.
2.10. Reverse phase high-performance liquid chromatography (RP-
HPLC)
Blood was collected from 2-month-old male standard-diet-fed mice
and then treated with 10 mL of 1% EDTA. In order to detect poly-
amines through RP-HPLC, blood samples underwent a dansylation
procedure. 100 ml of blood (previously treated with 5% TCA to allow
protein precipitation) and 1 ml of standard polyamines stock solutions
(1 mg/ml) were subjected to a derivatization process with dansyl
chloride according to Seiler [28]. After incubation at 40 C for 45 min
with dansyl chloride, mixtures were ﬁltered through a 0.45 mm RC-
membrane (ALBET-LabScience, Dassel/Relliehausen, Germany) and
injected into a HPLC apparatus (Agilent 1100) for analysis. The sep-
aration was executed on a Supelcosil LC 18 RP column (5 mm;
4,6  250 mm) maintained at 35 C. The mobile phase was
composed of water and methanol with the gradient elution system at a
ﬂow rate of 1.0 ml/min. The initial mobile phase contained 70%MOLECULAR METABOLISM 4 (2015) 846e856  2015The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.commethanol for 7 min. The gradient volume of methanol was 70e75% at
7e10 min, 75e90% at 10e20 min and 90e100% at 20e25 min.
The signal detection was through a Diode Array Detector (DAD) and
the chromatograms were recorded at a wavelength of 253 nm.
Polyamines calibration curves were obtained using dansylated poly-
amine standard solutions (concentrations ranging between 0.001 mg/
ml and 0.1 mg/ml). Polyamines concentration was normalized to total
protein concentration obtained with Bradford assay and expressed as
nmol/mg.
2.11. Statistical analyses
Data are reported as mean  SEM. All statistical analyses were per-
formed using Graphpad Prism 6.0c software. Unpaired two-tailed t-
tests were employed when 2 groups were compared, and one-way
ANOVA with Tukey correction for multiple comparisons were
employed when 3 or more groups were compared, and repeated
measures two-way ANOVA with Tukey correction for multiple com-
parisons were used when 3 or more groups were compared over a
time-course.accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 849
Figure 2: SIRT6 generated from Sirt6BAC is functionally competent. (A) Fre-
quency of viable mice per genotype observed at 4-week of age, shown as a percentage
of the expected Mendelian ratio. Mice were fed on a standard diet. (B) Body length
(n ¼ 9e13 per group) and (C) body weight (n ¼ 9e13 per group) of 3-week-old mice
fed on a standard diet. Values are mean  S.E.M. Statistics were analyzed using one-
way ANOVA with Tukey correction for multiple comparisons (****p < 0.0001).
Original article3. RESULTS
3.1. Generation and validation of Sirt6BAC mice
To determine the role of SIRT6 on energy and glucose homeostasis, we
generated genetically-engineered mice harboring bacterial artiﬁcial
chromosome (BAC) DNA containing 70.7 kb upstream and 109.3 kb
downstream sequences ﬂanking the mouse Sirt6 gene (Sirt6BAC mice)
(Figure 1A). In several tissues of Sirt6BAC mice, SIRT6 protein level
was found to be two to four times greater than wild-type controls
(Figures 1B,C and S1), suggesting that DNA sequences contained in
the BAC include the crucial transcriptional regulatory elements of the
endogenous Sirt6 gene. Of note, this magnitude of SIRT6 over-
expression found in Sirt6BAC mice is physiological as it approximates
that which is observed in calorically restricted rodents [29].
Virtually all BAC-based transgenic approaches suffer from two major
confounders that may alter gene expression and hence cause phe-
notypes: 1) the presence of additional coding and/or non-coding
sequences contained in the large BAC DNA sequences and 2) DNA
construct insertion site into the genome. As the genomic fragment
used to generate Sirt6BAC mice bears additional known mouse
genes (i.e.: AES, Ankrd24, BC025920, Gna11, Gna15, Tle2, and
Tle6), we assessed their mRNA contents and found them to be
increased in Sirt6BAC mice compared to wild-types (Figure 1D).
Hence, to disassociate the effect of SIRT6 overexpression from the
potential effect of non-SIRT6 BAC-born products and/or BAC insertion
site(s) on a given phenotype, we generated an additional control
genotype. This was accomplished by breeding the Sirt6BAC allele to
the Sirt6 null (Sirt6) allele [17]. This breeding scheme produced
three experimental genotypes that were used in this study: 1) wild-
type, 2) Sirt6BAC, and 3) Sirt6BAC; Sirt6/ mice. Of note, quanti-
tative PCR proﬁling of brain, gastrocnemius and liver indicated that
while AES, Ankrd24, BC025920, Gna11, Gna15, Tle2, and Tle6
mRNA levels are similarly increased in Sirt6BAC and Sirt6BAC;
Sirt6/ mice the latter showed reduced Sirt6 mRNA level compared
to the former genotype (Figure 1D). Also, while SIRT6 protein level is
signiﬁcantly increased in several tissues of Sirt6BAC mice compared
to wild-type controls (Figures 1B,C and S1), it is similar between
gastrocnemius of Sirt6BAC; Sirt6/ mice and wild-type controls
(Figure S1).
To validate the functional competence of BAC-DNA-derived SIRT6
protein, the ability of Sirt6BAC allele to rescue the phenotypes dis-
played by Sirt6/ mice was assessed. Among other defects, Sirt6/
mice have increased early-postnatal mortality and reduced body length
and weigh compared to wild-type mice [17]. These aberrancies were
all rescued by introduction of Sirt6BAC allele in the Sirt6 null back-
ground. Indeed, while viability, body length and weight were all
reduced in Sirt6/ mice (as predicted) all these parameters were
found to be normal in Sirt6BAC; Sirt6/ mice (Figure 2AeC).
Collectively, these data demonstrate that Sirt6BAC mice physiologically
overexpress functionally competent SIRT6 protein.
3.2. Normal energy balance in Sirt6BAC mice
To determine the effect of physiological overexpression of SIRT6 on
energy homeostasis, we measured body weight and composition of
Sirt6BAC mice, and Sirt6BAC; Sirt6/ and wild-type controls either
fed on a standard chow or on a HCD. In both feeding contexts, body
weight, fat and lean mass were all similar between Sirt6BAC, Sirt6-
BAC; Sirt6/, and wild-type mice (Figure 3AeF). Together, these data
demonstrate that physiological overexpression of SIRT6 neither affects
energy homeostasis nor protects from, or predisposes to, developing
diet-induced obesity.850 MOLECULAR METABOLISM 4 (2015) 846e856  2015 The Authors. Published by Elsevier Gmb3.3. Improved glucose homeostasis in Sirt6BAC mice
To determine the impact of physiological overexpression of SIRT6 on
glucose homeostasis, we measured several parameters of glucose
metabolism in Sirt6BAC mice and controls. Data shown in Figure 4A
indicate that in standard chow and HCD feeding conditions, 16-week-
old Sirt6BAC mice have reduced circulating glucose levels compared
to controls indicating that these mice are protected from developing
diet-induced T2DM. Of note, circulating glucose levels were not
different between Sirt6BAC; Sirt6/ and wild-type HCD-fed mice
(Figure 4A) hence suggesting that the glycemia phenotype shown by
Sirt6BAC mice is very likely the result of SIRT6 overexpression. The
improved hyperglycemia concomitant with unchanged circulating fed
(Figure 4B) and fasting (ng/mL; mean  SEM: wild-
types ¼ 0.53  0.058; Sirt6BAC mice ¼ 0.51  0.02; Sirt6BAC;
Sirt6/ mice ¼ 0.53  0.060; n ¼ 9e15 per group, p > 0.05)
insulin level hinted that Sirt6BAC mice may exhibit enhanced insulin
sensitivity.
To further investigate the effects of SIRT6 overexpression on glucose
metabolism, Sirt6BAC mice and controls were assessed for pyruvate
and glucose tolerance. In both feeding conditions, Sirt6BAC mice
exhibited reduced glycemic excursions during these tests
(Figure 4CeF). Of note, the improved pyruvate and glucose handling
were more pronounced in the HCD feeding context. These phenotypes
of Sirt6BAC mice are very likely the result of SIRT6 overexpression
because Sirt6BAC; Sirt6/ mice displayed intermediate degrees of
glycemic excursions during these tests (Figure 4CeF). Collectively,
our data indicate that physiological overexpression of SIRT6 reduces
glycemia and improves the glucose imbalance brought on HCD
feeding.H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Sirt6BAC mice display normal body weight, fat mass and lean mass. (A) Body weight, (B) body fat weight, and (C) body lean weight of mice in chow diet context
(n ¼ 14e21 per group). (D) Body weight, (E) body fat weight, and (F) body lean weight of mice in HCD context (n ¼ 10e14 per group). Values are mean  S.E.M. Statistics were
analyzed using a repeated measures two-way ANOVA with Tukey correction for multiple comparisons.3.4. Enhanced insulin sensitivity in liver and skeletal muscle of
Sirt6BAC mice
One possible explanation for the improved glucose homeostasis dis-
played by Sirt6BAC mice is enhanced insulin sensitivity. To directly test
this hypothesis, hyperinsulinemic-euglycemic clamp assays were
performed. During the clamp, insulin was infused to achieve hyper-
insulinemia while D-glucose was infused through the same intravenous
line at modulated rates to maintain euglycemia. In agreement with the
aforementioned data suggestive of increased insulin sensitivity of
Sirt6BAC mice, the glucose infusion rate (GIR) (Figure 5A) needed to
clamp euglycemia (Figure 5B) was greatly increased in chow-fed
Sirt6BAC mice compared to wild-type littermates. Basal endogenous
glucose appearance rate (EndoRa) (Figure 5C) and basal glucose
disposal rate (Rd) (Figure 5D) were not signiﬁcantly different between
Sirt6BAC mice and wild-type controls. During the clamp however, the
ability of insulin to suppress endogenous glucose production was
signiﬁcantly enhanced in Sirt6BAC mice compared to wild-type con-
trols (Figure 5C). Insulin-stimulated glucose disposal was also
increased in Sirt6BAC mice compared to wild-type controls
(Figure 5D).
To determine the relative contributions of certain tissues to glucose
disposal, the amounts of exogenously administered radiolabeled
glucose analog 2[14C]deoxyglucose were measured in several tissues.MOLECULAR METABOLISM 4 (2015) 846e856  2015The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comAs shown in Figure 5E, insulin-stimulated glucose uptake was
enhanced in Sirt6BAC mice in both gastrocnemius and soleus muscle,
but not in brain, interscapular brown adipose, or epididymal adipose
tissue. The whole-body glycolytic rate as percent of glucose disposal
(Figure 5F) was not found to be signiﬁcantly different between geno-
types. Overall, these data demonstrate that insulin sensitivity is
selectively augmented in liver and skeletal muscle of Sirt6BAC mice.
To independently assess in vivo insulin sensitivity, we used a well-
established biochemical approach. The level of phosphorylated AKT
(p-AKT) following a bolus of insulin has been used as measure of the
ability of the hormone to activate its receptor [10]. Intraperitoneal in-
sulin administration enhanced p-AKT/AKT ratio in gastrocnemius of
Sirt6BAC, Sirt6BAC; Sirt6/, and wild-type mice (Figure 6A,B). Of
note, while the ability of insulin to induce phosphorylation of AKT was
signiﬁcantly increased in gastrocnemius of Sirt6BAC compared to wild-
type mice (Figure 6A), it was not different between Sirt6BAC; Sirt6/
and wild-type controls (Figure 6B). These results are in keeping with
data shown in Figure 5E and further support the idea that SIRT6
overexpression drives enhanced insulin sensitivity in Sirt6BAC mice.
3.5. Increased spermidine content in blood of Sirt6BAC mice
To gather insights on potential mechanisms by which SIRT6 over-
expression boosts insulin sensitivity we surveyed hepatic geneaccessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 851
Figure 4: Sirt6BAC mice exhibit improved glucose homeostasis. (A) Basal (non-postprandial) glycemia of 16-week-old mice fed on a chow diet (n ¼ 17e24 per group) and on
a HCD (n ¼ 9e12 per group). (B) Basal (non-postprandial) serum insulin levels of 16-week-old mice fed on a chow diet (n ¼ 9e15 per group) and on a HCD (n ¼ 8e10 per
group). (C) Intraperitoneal glucose (1.5 g/kg bodyweight) tolerance test and area under curve of mice at 11e13 weeks of age in the chow diet context (n ¼ 6e8 per group). (D)
Intraperitoneal glucose (1.5 g/kg bodyweight) tolerance test and area under curve of mice at 18e20 weeks of age in the HCD context (n ¼ 5e10 per group). (E) Intraperitoneal
pyruvate (2 g/kg bodyweight) tolerance test and area under curve of mice at 25e26 weeks of age in the chow diet context (n ¼ 5e8 per group). (F) Intraperitoneal pyruvate (2 g/
kg bodyweight) tolerance test and area under curve of mice at 26e28 weeks of age in the HCD context (n ¼ 5e10 per group). Values are mean  S.E.M. Panel A, B and C-F (area
under curve): Statistics were analyzed using one-way ANOVA with Tukey correction for multiple comparisons (*p < 0.05). Panel CeF: Statistics were analyzed using repeated
measures two-way ANOVA with Tukey correction for multiple comparisons (*p < 0.05, **p < 0.01, ****p < 0.0001 Wild-type vs. Sirt6BAC), (yp < 0.05, yyp < 0.01 Wild-type vs.
Sirt6BAC; Sirt6/), (zp < 0.05, zzzp < 0.001 Sirt6BAC vs. Sirt6BAC; Sirt6/).
Original articleexpression and whole-blood polyamine content by qPCR and RP-
HPLC, respectively. Our results indicate increased mRNA content of
the glycolytic enzymes ATP-dependent 6-phosphofructokinase
(PFKL) and liver-type pyruvate kinase (LPK) in liver of Sirt6BAC
mice compared to wild-types (Figure S2). Furthermore, our data
indicate increased mRNA content of Elovl6, Acetyl-CoA carboxylase-b
(ACCb), and Fatty acid transport protein 5 (FATP5) in liver of Sirt6BAC
mice compared to wild-types (Figure S2). However, we found no
difference in serum triglyceride level between 16 and 20-week-old
Sirt6BAC and wild-type mice fed on a standard diet (ng/dL;
mean  SEM: wild-types ¼ 146  12; Sirt6BAC mice ¼ 139  16;
serum was collected from mice that were fasted over-night, n ¼ 6
per group, p > 0.05).
Due to important role of polyamines on energy metabolism [30], we
also assessed their level and found that total polyamines and sper-
midine contents are signiﬁcantly higher in blood of Sirt6BAC mice
compared to wild-types (Figure 7A,B). Collectively, these results
suggest that SIRT6 overexpression improves glucose/insulin homeo-
stasis in part by enhancing circulating spermidine contents and hepatic
glucose and lipid metabolism.852 MOLECULAR METABOLISM 4 (2015) 846e856  2015 The Authors. Published by Elsevier Gmb4. DISCUSSION
Due to the staggering number of people suffering from defects in
energy and glucose homeostasis and the shortcomings of current
therapies, there is a pressing need for developing better approaches
for the treatment of obesity and T2DM [1]. Several genetic studies have
recently provided support for the idea that activation of SIRT1 (one of
three mammalian nuclear sirtuin members) leads to improved meta-
bolic homeostasis in the context of hyper-caloric feeding [8e11,31e
34]. However, the role of another nuclear-localized sirtuin, namely
SIRT6, in metabolism is controversial. Indeed, Sirt6 loss- and gain-of-
function studies have brought about counterintuitive and outwardly
incongruent results, rendering it difﬁcult to determine whether acti-
vation or inhibition of SIRT6 would result in beneﬁcial metabolic out-
comes [17e19,21e23,35]. These apparently paradoxical ﬁndings
may be the result of the following non-mutually exclusive possibilities:
i) reduced glycemia and body adiposity displayed by Sirt6 null mice
may not be direct consequence of SIRT6 deﬁciency, but secondary
effects due to other serious abnormalities (e.g.: colitis, lymphopenia,
etc.) caused by this mutation [17], ii) reduced glycemia and bodyH. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: Sirt6BAC mice exhibit enhanced insulin sensitivity. (A) Glucose infusion rate (GIR) (mg glucose/kg bodyweight/minute) (B) Blood glucose (mg/dL) (C) Endogenous
glucose appearance (EndoRa) (mg/kg bodyweight/minute) (D) Glucose disposal (Rd) (mg/kg bodyweight/minute) (E) Tissue glucose uptake (Rg) (mmol/100 g tissue/minute) (F)
Glycolytic rate (% of Rd). n ¼ 6e8 per group. All mice were fed on a standard diet. Values are mean  S.E.M. Panels A&B: Statistics were analyzed using repeated measures one-
way ANOVA with Tukey correction for multiple comparisons (*p < 0.05, **p < 0.01). Panels C, D, E&F: Statistics were analyzed using unpaired two-tailed t-test (*p < 0.05,
**p < 0.01).
A
B
Figure 6: Sirt6BAC mice exhibit enhanced insulin-induced pAKT in gastrocnemius. Immunoblot and quantiﬁcation of Akt (Thr308) phosphorylation status relative to total AKT
(AKT) in gastrocnemius muscle 10 min after an intraperitoneal bolus of insulin (5 U/kg) or saline in (A) wild-type vs. Sirt6BAC mice and (B) wild-type vs. Sirt6BAC; Sirt6/ mice.
All mice were fasted 5 h before insulin or saline injection. All mice were age-matched and fed on a standard diet. Error bars represent s.e.m. Statistical analyses were done using
two-tailed unpaired Student’s t test. *P < 0.05; ***P < 0.001.
MOLECULAR METABOLISM 4 (2015) 846e856  2015The Authors. Published by Elsevier GmbH. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A B
Figure 7: Sirt6BAC mice exhibit enhanced spermidine level in blood. (A) Total polyamine content and (B) polyamine proﬁle of putrescine (Put), spermidine (Spd), and
spermine (Spm) in whole blood of 2-month-old wild-type (n ¼ 12) and Sirt6BAC (n ¼ 7) mice fed on a standard diet. Error bars represent s.e.m. Statistical analyses were done
using two-tailed unpaired Student’s t test. *P < 0.05.
Original articleadiposity displayed by SIRT6-overexpressor mice may be due to
inherent confounding effects of the unnatural chicken bActin promoter/
CMV enhancer-driven regulation of Sirt6 expression in these mutants
[22].
To gather insights about the effects of systemic and moderate acti-
vation of SIRT6, we genetically-engineered mice that eutopically and
physiologically overexpress SIRT6. As the exogenously introduced Sirt6
gene was under the control of its own natural promoter, SIRT6 over-
expression in these Sirt6BAC mice mimicked SIRT6 expression in
calorically restricted rodents (Figures 1 and S1) [29]. Importantly, the
approach we used is strikingly different from the one Kanﬁ and col-
leagues employed. In fact, in the Kanﬁ and colleagues’ model, the
artiﬁcial chicken bActin promoter/CMV enhancer drives Sirt6 expres-
sion at non-physiological levels and probably in cell-types that would
not normally express SIRT6 [22]. These shortcomings cast doubt on
the interpretations of results gathered from this mutant. It is also
important to note the limitations of our Sirt6BAC mouse model. The
major caveat of this method is the presence of large genomic se-
quences ﬂanking the mouse Sirt6 gene (Figure 1A). While these large
sequences are needed for Sirt6 transcriptional ﬁdelity, they also
contain other known genes whose expression was also found to be
increased in Sirt6BAC mice (Figure 1D). Hence, overexpression of
these other genes could have contributed to the phenotypes displayed
by Sirt6BAC mice. Also, BAC DNA construct insertion site(s) into the
genome may have altered endogenous gene expression and hence
caused phenotypes in Sirt6BAC mice. While the generation and study
of another SIRT6 BAC line could be useful to address the latter this
approach cannot address the former issue. In fact, the likelihood that
two different BAC transgenic lines bear DNA construct cloned into the
same genomic site(s) is virtually zero. Therefore, as expression of
genes contained in the BAC likely depends on DNA construct insertion
site(s) it is virtually impossible to assure equal expression of SIRT6 and
also non-SIRT6 BAC-born products in different tissues of two different
lines. Another approach would be to disrupt Sirt6 sequences in BAC
DNA construct and use this modiﬁed BAC DNA lacking the possibility to
overexpress SIRT6 as a negative control line (hereafter referred to as
Sirt6minusBAC mice). Again, while this approach is suitable to address854 MOLECULAR METABOLISM 4 (2015) 846e856  2015 The Authors. Published by Elsevier Gmbpotential insertion site effects, it cannot guarantee equal tissue-
speciﬁc overexpression of BAC-born products between Sirt6mi-
nusBAC and Sirt6BAC mice. Hence, the Sirt6minusBAC mice cannot
serve as controls to Sirt6BAC mice. On the other hand, BAC DNA
insertion site is identical between Sirt6BAC; Sirt6/ and Sirt6BAC
mice. The only appreciable difference between these two lines is SIRT6
expression which in Sirt6BAC mice is enhanced while in Sirt6BAC;
Sirt6/ mice is almost normal (Figures 1B,C,D and S1). Hence, if a
given phenotype were to be observed in Sirt6BAC mice and displayed
at an intermediate degree or not displayed by Sirt6BAC; Sirt6/ mice,
then the given phenotype is very likely the consequence of Sirt6
overexpression. Thus, to dissociate potential effects of BAC DNA
insertion site and/or overexpression of non-SIRT6 BAC-born products
to SIRT6 overexpression we used Sirt6BAC; Sirt6/ mice as controls.
Our study indicates that SIRT6 overexpression underlies the improved
glucose/insulin proﬁles displayed by Sirt6BAC mice. This conclusion
mainly rests on the following ﬁve observations: i) glycemia is signiﬁ-
cantly decreased in Sirt6BAC compared to wild-type HCD-fed mice;
however, this phenotype is not displayed by Sirt6BAC; Sirt6/ mice
(Figure 4A), ii) following a bolus of glucose, the glycemic level over
time is signiﬁcantly decreased in Sirt6BAC compared to wild-type
mice; however, this phenotype is not displayed by Sirt6BAC; Sirt6/
 mice (Figure 4C), iii) following a bolus of glucose, the glycemic level
over time is signiﬁcantly decreased in Sirt6BAC compared to wild-type
HCD-fed mice; however, this phenotype is displayed at an intermediate
degree by Sirt6BAC; Sirt6/ mice (Figure 4D); iv) following a bolus of
pyruvate, the glycemic level over time is signiﬁcantly decreased in
Sirt6BAC compared to wild-type HCD-fed mice; however, this
phenotype is displayed at an intermediate degree by Sirt6BAC; Sirt6/
 mice (Figure 4F), v) the ability of insulin to induce phosphorylation of
AKT is signiﬁcantly increased in gastrocnemius of Sirt6BAC mice
compared to wild-type controls; however, this phenotype is not dis-
played by Sirt6BAC; Sirt6/ mice (Figure 6).
It is worth noting that some of our data are somewhat unexpected. For
example, data shown in Figure 5D,E indicate that insulin-stimulated
glucose disposal is enhanced in Sirt6BAC mice relative to wild-type
controls. This is unexpected considering that loss of SIRT6 causesH. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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enhanced glucose transporter-1 and -4 (GLUT1 and GLUT4) membrane
localization and cell-autonomous glucose uptake [18,36]. The fact that
our Sirt6BAC mice do not display changes in body adiposity (Figure 3)
is not in keeping with Kanﬁ and colleagues’ results as their Sirt6
overexpressor model displays changes in this parameter [22]. While
future studies may be needed to explain these differences, we suggest
that these are the results of the different level and/or tissue distribution
of Sirt6 overexpression between our and Kanﬁ and colleagues’ model
[22].
In this study, we also attempted to shed light on potential mechanisms
underlying the beneﬁcial effect of SIRT6 on glucose homeostasis. Our
results indicate that these pathways include increased circulating
spermidine level and enhanced insulin sensitivity in liver and skeletal
muscle (Figures 5e7). Of note, the improved hepatic insulin sensitivity
of Sirt6BAC mice is in keeping with data indicating that SIRT6 inhibits
the activity of the gluconeogenic co-transcription factor peroxisome
proliferator-activated receptor-g coactivator 1-a and with the fact that
SIRT6 overexpression in liver improves hyperglycemia in diabetic mice
[23]. SIRT6 has recently been shown to interact with proteins of the
circadian core complex (e.g.: CLOCK and BMAL1) and to regulate
expression of several clock-controlled genes [35]. Considering the
important role of the circadian clock on metabolic homeostasis [37], it
is formally possible that changes in circadian clock function in liver and
skeletal muscle underlie the improved insulin sensitivity shown by
Sirt6BAC mice. To fully determine the role of SIRT6 gain-of-function in
speciﬁc tissues, future studies in tissue-restricted SIRT6 overexpressor
mice are warranted.
5. CONCLUSIONS
In summary, our data indicate that moderate, physiological over-
expression of SIRT6 enhances insulin sensitivity in skeletal muscle and
liver, engendering protective actions against diet-induced T2DM.
Hence, the present study provides support for the anti-T2DM effect of
SIRT6 and may pave the way for the development of SIRT6 agonists
aimed at treating T2DM.
DISCLOSURE SUMMARY
Authors have nothing to declare.
ACKNOWLEDGMENTS
We thank Carolyn Heckenmeyer, Ariane Widmer, and Anne Charollais in the Coppari
laboratory for technical support, Dr. Raul Mostoslavsky at Harvard Medical School for
providing the Sirt6 null mice, the transgenic core facility at the University of Texas
Southwestern Medical Center (USA), and Dr. Christelle Veyrat-Durebex at the
glucose/insulin clamp platform at University of Geneva (Switzerland) (http://www.
medecine.unige.ch/phenotypage/clampglucose.php). This work was supported by
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (graduate student
fellowship to R.M.I.), Juvenile Diabetes Research Foundation (Post-doctoral fellow-
ship 3-2011-405 to T.F.), American Heart Association (Scientist Development Grant
14SDG17950008 to T.F.), European Commission (Marie Curie Career Integration
Grant 320898 and ERC-Consolidator Grant 614847 to R.C.), and the Swiss National
Science Foundation (310030_146533/1 to R.C.). This work has also received sup-
port from the Louis-Jeantet Foundation and the Fondation Pour Recherches Medi-
cales of the University of Geneva (to R.C.).
CONFLICT OF INTEREST
None declared.MOLECULAR METABOLISM 4 (2015) 846e856  2015The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comAPPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.
molmet.2015.09.003.
REFERENCES
[1] Vianna, C.R., Coppari, R., 2011. A treasure trove of hypothalamic neuro-
circuitries governing body weight homeostasis. Endocrinology 152(1):11e18.
[2] Coppari, R., Bjorbaek, C., 2012. Leptin revisited: its mechanism of action and
potential for treating diabetes. Nature Reviews Drug Discovery 11(9):692e
708.
[3] Maahs, D.M., Rewers, M., 2006. Editorial: Mortality and renal disease in type 1
diabetes mellituseprogress made, more to be done. The Journal of Clinical
Endocrinology and Metabolism 91(10):3757e3759.
[4] Steffes, M.W., Sibley, S., Jackson, M., Thomas, W., 2003. Beta-cell function
and the development of diabetes-related complications in the diabetes control
and complications trial. Diabetes Care 26(3):832e836.
[5] Bluestone, J.A., Herold, K., Eisenbarth, G., 2010. Genetics, pathogenesis and
clinical interventions in type 1 diabetes. Nature 464(7293):1293e1300.
[6] Ramadori, G., Lee, C.E., Bookout, A.L., Lee, S., Williams, K.W., Anderson, J.,
et al., 2008. Brain SIRT1: anatomical distribution and regulation by energy
availability. The Journal of Neuroscience: The Ofﬁcial Journal of the Society for
Neuroscience 28(40):9989e9996.
[7] Ramadori, G., Konstantinidou, G., Venkateswaran, N., Biscotti, T., Morlock, L.,
Galie, M., et al., 2015. Diet-induced unresolved ER stress hinders KRAS-driven
lung tumorigenesis. Cell Metabolism 21(1):117e125.
[8] Ramadori, G., Gautron, L., Fujikawa, T., Vianna, C.R., Elmquist, J.K.,
Coppari, R., 2009. Central administration of resveratrol improves diet-induced
diabetes. Endocrinology 150(12):5326e5333.
[9] Ramadori, G., Fujikawa, T., Fukuda, M., Anderson, J., Morgan, D.A.,
Mostoslavsky, R., et al., 2010. SIRT1 deacetylase in POMC neurons is required
for homeostatic defenses against diet-induced obesity. Cell Metabolism 12(1):
78e87.
[10] Ramadori, G., Fujikawa, T., Anderson, J., Berglund, E.D., Frazao, R.,
Michan, S., et al., 2011. SIRT1 deacetylase in SF1 neurons protects against
metabolic imbalance. Cell Metabolism 14(3):301e312.
[11] Ramadori, G., Coppari, R., 2010. Pharmacological manipulations of CNS sir-
tuins: potential effects on metabolic homeostasis. Pharmacological Research
62(1):48e54.
[12] Coppari, R., Ramadori, G., Elmquist, J.K., 2009. The role of transcriptional
regulators in central control of appetite and body weight. Nature Clinical
Practice Endocrinology & Metabolism 5(3):160e166.
[13] Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., et al.,
2006. Resveratrol improves health and survival of mice on a high-calorie diet.
Nature 444(7117):337e342.
[14] Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C.,
Daussin, F., et al., 2006. Resveratrol improves mitochondrial function and
protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell
127(6):1109e1122.
[15] Ramadori, G., Coppari, R., 2011. Does hypothalamic SIRT1 regulate aging?
Aging 3(3):325e328.
[16] Kugel, S., Mostoslavsky, R., 2014. Chromatin and beyond: the multitasking
roles for SIRT6. Trends in Biochemical Sciences 39(2):72e81.
[17] Mostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R.,
Gellon, L., et al., 2006. Genomic instability and aging-like phenotype in the
absence of mammalian SIRT6. Cell 124(2):315e329.
[18] Zhong, L., D’Urso, A., Toiber, D., Sebastian, C., Henry, R.E., Vadysirisack, D.D.,
et al., 2010. The histone deacetylase Sirt6 regulates glucose homeostasis via
Hif1alpha. Cell 140(2):280e293.accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 855
Original article[19] Sundaresan, N.R., Vasudevan, P., Zhong, L., Kim, G., Samant, S., Parekh, V.,
et al., 2012. The sirtuin SIRT6 blocks IGF-Akt signaling and development of
cardiac hypertrophy by targeting c-Jun. Nature Medicine 18(11):1643e1650.
[20] Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., 1993. Adipose expression
of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.
Science 259(5091):87e91.
[21] Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., et al., 2013.
SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty
acyl lysine. Nature 496(7443):110e113.
[22] Kanﬁ, Y., Peshti, V., Gil, R., Naiman, S., Nahum, L., Levin, E., et al., 2010.
SIRT6 protects against pathological damage caused by diet-induced obesity.
Aging Cell 9(2):162e173.
[23] Dominy Jr., J.E., Lee, Y., Jedrychowski, M.P., Chim, H., Jurczak, M.J.,
Camporez, J.P., et al., 2012. The deacetylase Sirt6 activates the acetyl-
transferase GCN5 and suppresses hepatic gluconeogenesis. Molecular Cell
48(6):900e913.
[24] Balthasar, N., Coppari, R., McMinn, J., Liu, S.M., Lee, C.E., Tang, V., et al.,
2004. Leptin receptor signaling in POMC neurons is required for normal body
weight homeostasis. Neuron 42(6):983e991.
[25] Lee, E.C., Yu, D., Martinez de Velasco, J., Tessarollo, L., Swing, D.A.,
Court, D.L., et al., 2001. A highly efﬁcient Escherichia coli-based chromosome
engineering system adapted for recombinogenic targeting and subcloning of
BAC DNA. Genomics 73(1):56e65.
[26] Fujikawa, T., Berglund, E.D., Patel, V.R., Ramadori, G., Vianna, C.R., Vong, L.,
et al., 2013. Leptin engages a hypothalamic neurocircuitry to permit survival in
the absence of insulin. Cell Metabolism 18(3):431e444.
[27] Berglund, E.D., Vianna, C.R., Donato Jr., J., Kim, M.H., Chuang, J.C., Lee, C.E.,
et al., 2012. Direct leptin action on POMC neurons regulates glucose ho-
meostasis and hepatic insulin sensitivity in mice. The Journal of Clinical
Investigation 122(3):1000e1009.856 MOLECULAR METABOLISM 4 (2015) 846e856  2015 The Authors. Published by Elsevier Gmb[28] Seiler, N., 1983. Liquid chromatographic methods for assaying polyamines
using prechromatographic derivatization. Methods in Enzymology 94:10e25.
[29] Kanﬁ, Y., Shalman, R., Peshti, V., Pilosof, S.N., Gozlan, Y.M., Pearson, K.J.,
et al., 2008. Regulation of SIRT6 protein levels by nutrient availability. FEBS
Letters 582(5):543e548.
[30] Kraus, D., Yang, Q., Kong, D., Banks, A.S., Zhang, L., Rodgers, J.T., et al.,
2014. Nicotinamide N-methyltransferase knockdown protects against diet-
induced obesity. Nature 508(7495):258e262.
[31] Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A.,
North, B.J., et al., 2012. SIRT1 is required for AMPK activation and the
beneﬁcial effects of resveratrol on mitochondrial function. Cell Metabolism
15(5):675e690.
[32] Banks, A.S., Kon, N., Knight, C., Matsumoto, M., Gutierrez-Juarez, R.,
Rossetti, L., et al., 2008. SirT1 gain of function increases energy efﬁciency and
prevents diabetes in mice. Cell Metabolism 8(4):333e341.
[33] Coppari, R., 2012. Metabolic actions of hypothalamic SIRT1. Trends in
Endocrinology and Metabolism: TEM 23(4):179e185.
[34] Pﬂuger, P.T., Herranz, D., Velasco-Miguel, S., Serrano, M., Tschop, M.H.,
2008. Sirt1 protects against high-fat diet-induced metabolic damage. Pro-
ceedings of the National Academy of Sciences of the United States of America
105(28):9793e9798.
[35] Masri, S., Rigor, P., Cervantes, M., Ceglia, N., Sebastian, C., Xiao, C., et al.,
2014. Partitioning circadian transcription by SIRT6 leads to segregated control
of cellular metabolism. Cell 158(3):659e672.
[36] Xiao, C., Kim, H.S., Lahusen, T., Wang, R.H., Xu, X., Gavrilova, O., et al., 2010.
SIRT6 deﬁciency results in severe hypoglycemia by enhancing both basal and
insulin-stimulated glucose uptake in mice. The Journal of Biological Chemistry
285(47):36776e36784.
[37] Sahar, S., Sassone-Corsi, P., 2012. Regulation of metabolism: the circadian clock
dictates the time. Trends in Endocrinology and Metabolism: TEM 23(1):1e8.H. This is an open accessarticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
